What is Bot Image?
Bot Image, Inc. is at the forefront of medical technology, specializing in the development of artificial intelligence and MRI-based solutions for cancer detection and diagnosis. The company's primary focus is on prostate cancer, where its flagship product, ProstatID, has achieved a significant milestone as the first FDA-cleared AI software for prostate cancer screening, detection, and diagnosis in North America. ProstatID is designed to empower urologists, primary care physicians, and imaging centers by enhancing diagnostic accuracy and improving patient care pathways. Complementing its core offerings, Bot Image also provides the MaleScan service, which delivers rapid, AI-supported diagnostic reports to physicians and patients, streamlining the diagnostic process.
How much funding has Bot Image raised?
Bot Image has raised a total of $1.5M across 3 funding rounds:
Multiple Rounds
$1.5M
Private Equity (2025): $200K, investors not publicly disclosed
Private Equity (2025): $1M, investors not publicly disclosed
Private Equity (2025): $280K, investors not publicly disclosed
What's next for Bot Image?
The substantial enterprise-level funding and recent strategic investment position Bot Image for accelerated growth and market expansion. This capital infusion is expected to fuel further research and development into its AI diagnostic technologies, potentially broadening its application beyond prostate cancer. The company's focus on securing FDA clearance and developing proprietary software like ProstatID suggests a strategy aimed at establishing a dominant presence in the medical AI sector. Future endeavors will likely involve scaling its commercial operations, forging strategic partnerships within the healthcare ecosystem, and potentially exploring new diagnostic areas where AI can significantly impact patient outcomes and healthcare efficiency.
See full Bot Image company page
